Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions

Reuters

06-21

Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions

Structure Therapeutics Inc. $(GPCR)$, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545105283"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545105283\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545105283?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-21 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545105283","market":"fut","top_or_hot":-1,"title":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. <a href=\"https://laohu8.com/S/GPCR\">$(GPCR)$</a>, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStructure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-21 07:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. <a href=\"https://laohu8.com/S/GPCR\">$(GPCR)$</a>, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL20pdcm:1","article_id":"2545105283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545105283","pubTimestamp":1750462216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 20, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4599":"减肥药","BK4007":"制药","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Structure Therapeutics Inc.在ADA科学会议上公布了口服小分子胰淀素激动剂ACCG-2671的有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":0.9,"NDAQ":0.9},"content_text":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n    \n\n        Structure Therapeutics Inc. $(GPCR)$, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}